Shares of BeyondSpring Inc. (NASDAQ:BYSI) have earned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.

Analysts have set a 1-year consensus price objective of $51.00 for the company and are expecting that the company will post ($0.69) EPS for the current quarter, according to Zacks. Zacks has also given BeyondSpring an industry rank of 110 out of 265 based on the ratings given to its competitors.

Several research firms recently commented on BYSI. Maxim Group began coverage on shares of BeyondSpring in a report on Tuesday, August 22nd. They issued a “buy” rating and a $52.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price objective on shares of BeyondSpring in a report on Monday, August 21st. Zacks Investment Research raised shares of BeyondSpring from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Finally, Rodman & Renshaw raised their price objective on shares of BeyondSpring from $43.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, July 14th.

An institutional investor recently bought a new position in BeyondSpring stock. Tanaka Capital Management Inc. purchased a new stake in BeyondSpring Inc. (NASDAQ:BYSI) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 21,322 shares of the company’s stock, valued at approximately $914,000. BeyondSpring accounts for about 2.1% of Tanaka Capital Management Inc.’s investment portfolio, making the stock its 16th largest holding. Tanaka Capital Management Inc. owned 0.10% of BeyondSpring at the end of the most recent reporting period. 1.23% of the stock is currently owned by hedge funds and other institutional investors.

Shares of BeyondSpring (NASDAQ:BYSI) traded up 2.67% during midday trading on Friday, hitting $36.50. The company had a trading volume of 1,391 shares. BeyondSpring has a 12-month low of $16.55 and a 12-month high of $48.49. The company’s market capitalization is $833.81 million. The company’s 50-day moving average price is $38.95 and its 200 day moving average price is $32.02.

WARNING: “Zacks: BeyondSpring Inc. (BYSI) Given Consensus Recommendation of “Strong Buy” by Brokerages” was posted by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/09/08/zacks-beyondspring-inc-bysi-given-consensus-recommendation-of-strong-buy-by-brokerages.html.

BeyondSpring Company Profile

BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).

Get a free copy of the Zacks research report on BeyondSpring (BYSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BeyondSpring Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring Inc. and related companies with MarketBeat.com's FREE daily email newsletter.